2023 international evidence-based guideline pcos glp-1 receptor agonist The dual impact of agonists on metabolic and reproductive health in polycystic ovary syndrome: insights from human and animal trials PDF) Recommendations from the 2023
Description
Considering route of administration, the market is divided into parenteral and oral
Oral GLP-1 agonists havent quite caught on yet, primarily due to (1) issues with absorption, which necessitates higher dosing than injectables and may impact efficacy, and (2) fasting restrictions (must be taken on an empty stomach)
They signal that Lilly could gain big-time market share in both these markets among patients who prefer oral administration
The clinical significance of anti-exenatide antibody formation is unknown at this time
